Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ:PROK)

2.130 +0.040 (+1.91%)

Streaming Delayed Price Updated: 10:34 AM EDT, Apr 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	145,524
Open	2.130
Bid (Size)	2.120 (1,000)
Ask (Size)	2.130 (600)
Prev. Close	2.090
Today's Range	2.115 - 2.165
52wk Range	0.5400 - 7.130
Shares Outstanding	61,540,231
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

March 25, 2026

Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization

From ProKidney

Via GlobeNewswire

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

March 18, 2026

From ProKidney

Via GlobeNewswire

Performance

YTD	-4.5%	-4.5%
1 Month	+9.8%	+9.8%
3 Month	-0.5%	-0.5%
6 Month	-35.5%	-35.5%
1 Year	+190.6%	+190.6%

More News

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From ProKidney

Via GlobeNewswire

ProKidney Corp (NASDAQ:PROK) Reports Q3 2025 Earnings and Clinical Progress ↗

November 10, 2025

Via Chartmill

Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern

November 10, 2025

Via MarketMinute

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

November 10, 2025

From ProKidney

Via GlobeNewswire

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

November 06, 2025

From ProKidney

Via GlobeNewswire

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

October 29, 2025

From ProKidney

Via GlobeNewswire

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

October 20, 2025

From ProKidney

Via GlobeNewswire

SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC ↗

October 02, 2025

Via Benzinga

Which stocks are experiencing notable movement on Friday? ↗

September 12, 2025

Via Chartmill

What's going on in today's session ↗

September 11, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 11, 2025

Via Benzinga

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

August 27, 2025

From ProKidney

Via GlobeNewswire

Prediction: Chamath Palihapitiya's $250 Million SPAC Could Create the Next Palantir for America's Energy Grid ↗

August 24, 2025

Via The Motley Fool

Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14% ↗

August 19, 2025

Via Benzinga

ProKidney Reports 78 Percent Gain in Q2 ↗

August 12, 2025

Via The Motley Fool

ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss ↗

August 12, 2025

Via Chartmill

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12, 2025

From ProKidney

Via GlobeNewswire

Meet the Biotech Stock That Rocketed 775% Higher ↗

July 22, 2025

Via The Motley Fool

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? ↗

July 17, 2025

Via The Motley Fool

Unusual volume stocks are being observed in Tuesday's session. ↗

July 15, 2025

Via Chartmill

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 15, 2025

Via Benzinga

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

July 15, 2025

From ProKidney

Via GlobeNewswire

These stocks are moving in today's session ↗

July 14, 2025

Via Chartmill

Frequently Asked Questions

Is ProKidney Corp. - Class A Ordinary Shares publicly traded?

Yes, ProKidney Corp. - Class A Ordinary Shares is publicly traded.

What exchange does ProKidney Corp. - Class A Ordinary Shares trade on?

ProKidney Corp. - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for ProKidney Corp. - Class A Ordinary Shares?

The ticker symbol for ProKidney Corp. - Class A Ordinary Shares is PROK on the Nasdaq Stock Market

What is the current price of ProKidney Corp. - Class A Ordinary Shares?

The current price of ProKidney Corp. - Class A Ordinary Shares is 2.130

When was ProKidney Corp. - Class A Ordinary Shares last traded?

The last trade of ProKidney Corp. - Class A Ordinary Shares was at 04/22/26 10:34 AM ET

What is the market capitalization of ProKidney Corp. - Class A Ordinary Shares?

The market capitalization of ProKidney Corp. - Class A Ordinary Shares is 131.08M

How many shares of ProKidney Corp. - Class A Ordinary Shares are outstanding?

ProKidney Corp. - Class A Ordinary Shares has 131M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.